Psoriasis, biologic therapy, and the pandemic of the 21st century

Article Page

Abstract

The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a significant impact on lives all over the world. The complexity related to the new coronavirus and the clinical syndrome it causes is not yet fully understood. The impact of COVID-19 on patients with psoriasis under biologic agents is continuously being observed in this rapidly changing pandemic. A case-by-case evaluation must be made by dermatologists, and the final decision should be discussed and decided by both the patient and the specialist. Observations reveal that immunosuppressive therapy may have a role in the treatment of this virus, placing emphasis on the scenario of safety through maintenance of therapy with biologic agents, especially when there are no signs or symptoms related to the infection or contact with an infected patient.

Keywords: biologic, coronavirus, COVID-19, SARS-CoV-2, psoriasis.

Citation: Nogueira M, Vender R, Torres T. Psoriasis, biologic therapy, and the pandemic of the 21st century. Drugs in Context 2020; 9: 2020-4-10. DOI: 10.7573/dic.2020-4-10

Contributions: All authors contributed equally to the preparation of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: Miguel Nogueira has no conflicts of interest. Ron Vender has participated in clinical trials and has received honoraria for acting as a consultant and/or as a speaker at events sponsored by AbbVie, Amgen, Boehringer-Ingelheim, Celgene, Galderma, GSK, Janssen, LEO-Pharma, Eli-Lilly, MSD, Novartis, UCB, and Pfizer. Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Biocad, LEO-Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung Bioepis, Sanofi-Genzyme, and Sandoz. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/05/dic.2020-4-10-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Nogueira M, Vender R, Torres T. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Nogueira M, Vender R, Torres T. https://doi.org/10.7573/dic.2020-4-10. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://drugsincontext.com/psoriasis,-biologic-therapy,-and-the-pandemic-of-the-21st-century

Correspondence: Tiago Torres, Department of Dermatology, Centro Hospitalar Universitário do Porto, and Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal. torres.tiago@outlook.com

Provenance: submitted; externally peer reviewed.

Submitted: 20 April 2020; Peer review comments to author: 29 April 2020; Revised manuscript received: 30 April 2020; Accepted: 1 May 2020; Publication date: 14 May 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF